MIXED RESULTS FOR KX-826 PHASE 3 TRIALS
A Reddit post reveals the Chinese Phase 3 trials of KX-826 (Pyrilutamide) yielded satisfactory, but not exceptional, results. The trials, free from serious side effects or adverse events, showed positive hair growth over 24 weeks compared to the baseline. However, in comparison with the placebo group, the total area hair count (TAHC) improvements in the KX-826 group weren’t statistically significant, though there was a noticeable trend towards efficacy.
Kintor is pushing forward with additional KX-826 trials in both the US and China to treat androgenetic alopecia. The company’s swift release of these findings is commendable, with an official press release expected soon.
KINTOR PHARMA’S ONGOING EFFORTS FOR ANDROGENETIC ALOPECIA
This dynamic and well-funded company is advancing Phase 2 and 3 trials in the US and China for two androgenetic alopecia products.
- Two androgen receptor-targeting products: GT20029 (a degrader) and KX-826 (an antagonist), with trials in both China and the US for male and female androgenetic alopecia patients.
- This totals 24 different trial developments, with over half already completed.
- GT20029, utilizing Kintor’s Proteolysis Targeting Chimera (PROTAC) platform, is the first topical androgen receptor (AR) compound (AR-PROTAC) in clinical trials. It degrades AR protein via the E3 ubiquitin ligase pathway and showed no notable side effects in preclinical studies.
- KX-826, Kintor’s primary male pattern hair loss treatment, is an AR antagonist currently in Phase 3 trials.
Kintor’s website also discusses competing AR antagonist products and hair loss, like Cassiopea’s Breezula (Clascoterone).
KX-826’S PHASE 3 PROGRESS
KX-826 is in advanced Phase 3 stages in China and early stages in the US for both men and women. Kintor is also conducting a second Phase 3 trial in China for KX-826’s long-term safety.
A Chinese reader provided a translation of Kintor’s recent presentation. KX-826, a topical AR antagonist, blocks androgen signaling, reducing hair follicle miniaturization and promoting hair growth. It rapidly metabolizes into inactive metabolites, ensuring safety.
In Phase 2 trials, KX-826 demonstrated significant improvement in non-vellus hair count at 0.5% concentration. Phase 3 trials, involving five separate studies (two in China, three in the US), are progressing, with the last Chinese trial for male alopecia nearing completion.
GT2009’S PHASE 2 ADVANCEMENTS
Kintor’s recent update announced the completion of patient enrollment for Phase 2 trials of GT20029 for male pattern hair loss in China, with these trials nearing conclusion and soon to commence in the US.
CONCLUSION
Kintor Pharmaceutical remains a key player in the development of treatments for androgenetic alopecia, with a diverse portfolio of products in various stages of clinical trials. While the Phase 3 results of KX-826 have been mixed, the company’s commitment to continuing research and development in this area is evident. The advancements in both KX-826 and GT20029 trials demonstrate Kintor’s dedication to addressing hair loss through innovative treatments. The hair loss treatment community eagerly awaits further updates, particularly as the Phase 3 trials for KX-826 approach their conclusion and GT20029 moves closer to US trials, marking significant milestones in the journey to provide effective solutions for androgenetic alopecia.
View the full Kintor Pharma announcement here.
